Text Size

Aromatase Inhibitor Host Factors Study

This study is currently recruiting participants.
Verified January 2013 by Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Sponsor:
Information provided by (Responsible Party):
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
ClinicalTrials.gov Identifier:
NCT01669343
First received: August 15, 2012
Last updated: January 23, 2013
Last verified: January 2013
History of Changes
  Purpose

The purpose of this study is to examine how key patient factors, including body size affect how well letrozole suppresses circulating estrogen levels.

This study has two components: (1) Part A - an observational phase to evaluate the impact of vitamin D and obesity on estrogen suppression in post-menopausal women already receiving letrozole treatment, and (2) Part B - an interventional phase for women with body mass index (BM) > 25 kg/m2.

If BMI or other patient factors reduce the effectiveness of letrozole, modifications to treatment recommendations and studies to test higher dosing of letrozole may be needed to maximize the benefit of this treatment and minimize the risk of the breast cancer coming back.


Condition Intervention
Breast Neoplasms
 Drug: Letrozole

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole

Resource links provided by NLM:

Drug Information available for: Letrozole
U.S. FDA Resources

Further study details as provided by Samuel Lunenfeld Research Institute, Mount Sinai Hospital:

Primary Outcome Measures:
  • Change from Baseline in Serum Estradiol at day 28 [ Time Frame: baseline and day 28 ] [ Designated as safety issue: No ]
  • Change in Serum Estradiol from baseline and day 28 [ Time Frame: day 58 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Plasma Letrozole [ Time Frame: baseline, day 29 and day 58 ] [ Designated as safety issue: No ]
  • Endocrine Symptoms [ Time Frame: baseline, day 29 (end of part A) and day 58 (end of part B) ] [ Designated as safety issue: Yes ]

Other Outcome Measures:
  • Musculoskeletal Symptoms [ Time Frame: baseline (day 1), day 29 (end of part A) and day 58 (end of part B) ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 140
Study Start Date: September 2012
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Part A letrozole 2.5 mg
letrozole 2.5 mg tablet,once daily for 28 days
 Drug: Letrozole
Active Comparator Arm receives 2.5 mg letrozole and Experimental Arm receives 5.0 mg letrozole
Experimental: Part B letrozole 5.0 mg
letrozole 2.5 mg tablet, two tablets,once daily for 28 days
 Drug: Letrozole
Active Comparator Arm receives 2.5 mg letrozole and Experimental Arm receives 5.0 mg letrozole

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Postmenopausal female patients
  • histological confirmed diagnosis of ER and/or PR positive breast cancer (Stage I-III) who have completed local therapy
  • Currently prescribed and taking letrozole 2.5 mg daily for a minimum of 3 months
  • Willing to provide written informed consent to participate
  • for the experimental arm: all of the above and body mass index (BMI) > 25 kg/m2

Exclusion Criteria:

  • Known abnormal liver or renal function defined by:

    1. Serum Creatinine > 1.25 times institutional upper limit of normal (ULN) or Calculated Creatinine Clearance < 40 mL/min
    2. Serum Bilirubin, AST or ALT > 1.5 times ULN
  • Presence of persistent local or known metastatic cancer
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01669343

Contacts
Contact: Srikala Sridhar, M.D. 416-946-2662 srikala.sridhar@uhn.ca

Locations
Canada, Ontario
Mount Sinai Hospital Recruiting
Toronto, Ontario, Canada, M5G 1X5
Contact: Pamela J Goodwin, M.D.     416-586-8605     pgoodwin@mtsinai.on.ca    
Sub-Investigator: Pamela J Goodwin, MD            
Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G 1M9
Contact: Srikala Sridhar, MD     416-946-2662     srikala.sridhar@uhn.ca    
Women's College Hospital Not yet recruiting
Toronto, Ontario, Canada, M5S 1B1
Contact: Carol Townsley, MD     416-323-6400 ext 3297     Carol.Townsley@uhn.on.ca    
Sub-Investigator: Carol Townsley, MD            
Sponsors and Collaborators
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Investigators
Principal Investigator: Srikala Sridhar, MD Mount Sinai Hospital, New York
  More Information

No publications provided

Responsible Party: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
ClinicalTrials.gov Identifier: NCT01669343     History of Changes
Other Study ID Numbers: AI Host Factors
Study First Received: August 15, 2012
Last Updated: January 23, 2013
Health Authority: Canada: Health Canada

Keywords provided by Samuel Lunenfeld Research Institute, Mount Sinai Hospital:
Aromatase Inhibitors

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Letrozole
 Aromatase Inhibitors
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 16, 2013